Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04300686
Other study ID # TACTIC-SS
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 1, 2020
Est. completion date December 31, 2023

Study information

Verified date August 2021
Source Shanghai Zhongshan Hospital
Contact Rongyi Chen, PhD
Phone +8615221160538
Email chenry825@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. We classify TAK patients into 3 levels, including mild, moderate, and severe. And the biological agents tocilizumab and adalimumab are randomly prescribed in severe patients, to find out the relatively better treatment strategy, facilitating better intervention strategy in severe TAK patients.


Description:

The Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks an effective well-accepted intervention strategy. Previous studies have revealed that methotrexate, tofacitinib, adalimumab, and tocilizumab were effective in controlling disease activity and preventing disease relapse in some TAK patients, especially the latter two biological agents. However, we believed that different patients should be prescribed different drug combinations, i.e. personalized medicine, to obtain the optimal intervention effect. Here we tried to classify the TAK patients into three levels including mild, moderate, and severe, and prescribe different drug interventions to discover which biological agent is better in severe TAK patients. 1. Patients were classified as mild, moderate, and severe groups according to the disease severity of TAK patients. 1.1 Severe 1. Severe hypertension 1. Continuously upper limb systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg; 2. OR upper limb blood pressure cannot be measured if lower limb systolic blood pressure ≥200mmHg or diastolic blood pressure ≥120mmHg; 3. With target organ damage due to hypertension; 2. Aortic arch and its branches involved a. Multiple branches involved (two or more) and severe stenosis (stenosis rate ≥70%); b. stenosis rate ≥50%, accompanied by nervous system ischemic symptoms and/or signs; c. stenosis rate ≥50%, accompanied by a recent history of cerebrovascular events; 3. The carotid artery and its branches involved 1. Multiple branches (two or more) involved and severe stenosis (stenosis rate ≥70%); 2. stenosis rate ≥50%, accompanied by nervous system ischemic symptoms and/or signs; 3. stenosis rate ≥50%, accompanied by the recent history of cerebrovascular events; 4. Pulmonary artery involvement a. Chest tightness, hemoptysis, dyspnea, radionuclide pulmonary ventilation/blood perfusion imaging or CTA suggesting pulmonary artery thrombosis with respiratory failure (type I); b. Chest tightness, shortness of breath, and cardiac ultrasound suggesting severe pulmonary artery hypertension with cardiac function abnormality (NYHA class III and above); 5. The coronary artery involved 1. The onset of unstable angina pectoris or myocardial infarction; 2. Cardiac ultrasound indicating ischemic cardiomyopathy, NYHA class III and above; 6. The aortic valve and aortic root involved 1. Severe reflux of the aortic valve; 2. OR aortic valve leakage, annulus tearing; 3. OR aneurysm in the aortic root and/or ascending aortic (≥2 times in diameter); 4. OR dilation of the aortic root and/or ascending aorta (≥5cm in diameter); 5. OR dissection of the aortic root and/or ascending aorta; Any item of the above a - e is accompanied by abnormal cardiac function (NYHA III and above); 7. Renal artery involved a. Severe stenosis of renal artery secondary to malignant hypertension (blood pressure is still 180 / 120mmHg after treatment with three or more antihypertensive drugs) b. Severe renal artery stenosis accompanied by a progressive increase in serum creatinine or a reduction in glomerular filtration rate (GFR) of ≥25%; 8. Glucocorticoids and the traditional synthetic chemical immunosuppressants were of no use. And the disease is not well controlled with the severe injury of the organs. 1.2 Moderate 1. Hypertension a. Upper limb systolic blood pressure ≥160-180mmHg or / and diastolic blood pressure ≥100-110mmHg; b. OR upper limb blood pressure is unmeasurable or lower limb systolic blood pressure is ≥180mmHg or diastolic blood pressure is ≥100-110mmHg; 2. Aortic arch and its branches involved a. 1-2 vessels are involved with moderate stenosis (stenosis rate ≥50%-<70%); b. Dizziness occurs during physical activity, and symptoms disappear in the resting state; 3. The carotid artery and its branches involved a. Unilateral or bilateral vascular stenosis rate ≥50% -70%, with dizziness during light physical activity; 4. Pulmonary artery involved a. Radionuclide pulmonary ventilation/blood perfusion imaging or CTA indicates pulmonary vascular disease; chest tightness after activity; Cardiac ultrasound indicates moderate pulmonary artery hypertension (pressure> 40-60mmHg), with abnormal cardiac function (NYHA class Ⅱ); 5. Coronary artery involvement a. Chest tightness and chest pain after moderate activities, CTA showed 50% or more in coronary artery stenosis, abnormal cardiac function (NYHA class Ⅱ); 6. The aortic valve and aortic root involved 1. Moderate aortic regurgitation; 2. Aortic root and/or ascending aortic aneurysm (diameter <2 times); 3. Dilation of the aortic root and/or ascending aorta (diameter <5cm); Each item of a - c is accompanied by abnormal cardiac function (NYHA Class II); 7. Renal artery involvement a. Renal artery stenosis rate ≥50%, and blood pressure 160-180 / 110-120 (excluding 120) mmHg after treatment, or with left ventricular myocardial hypertrophy, hypertension and heart disease, CKD-II; 1.3 Mild 1. Hypertension 1. Upper limb systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg; 2. OR upper limb blood pressure is unmeasurable or lower limb systolic blood pressure is ≥140mmHg or diastolic blood pressure is ≥90mmHg; 2. Aortic arch and its branches involved a. Single or multiple lesions with mild stenosis (stenosis rate <50%), and without neurological ischemic symptoms and/or signs in daily activities; 3. The carotid artery and its branches involved a. Single or multiple lesions with mild stenosis (stenosis rate <50%) and no neurological ischemic symptoms and/or signs during daily activities; 4. The pulmonary artery involved 1. Cardiac ultrasound indicates mild or normal pulmonary artery pressure (pressure 30-40mmHg); 2. Imaging shows pulmonary arteritis or pulmonary artery stenosis, occlusion a and b, with chest tightness, shortness of breath, and hemoptysis without activity; cardiac function (NYHA I), normal blood gas analysis; 5. The coronary artery involved a. Chest tightness, shortness of breath, chest pain after inactivity; cardiac function (NYHA I); 6. The aortic valve and aortic root involved 1. Mild aortic regurgitation; 2. Aortic root and / or ascending aortic aneurysm-like expansion (diameter <1.5 times); a and b, each with cardiac function (NYHA I); 7. Renal artery involved a. Renal artery stenosis rate <50%, without/with mild hypertension (see 1), or normal serum creatinine, normal or slightly impaired glomerular filtration rate (GFR); 1.2. Based on the TAK patients in the ECTA cohort (Clinical trials. No: NCT03893136), we tried to compare the treatment efficacy of biological agents between tocilizumab (TCZ) and adalimumab (ADA) in severe TAK patients, with a pilot study. Other important detailed description of the study are listed as follows: 1. Basic treatment of prednisone: The initial prednisone dose is 40mg.qd.po, and maintained for 1 month. After 1 month's treatment, the dose is gradually tapered to 15mg by 5mg per 2 weeks. Subsequently, the dose is decreased to 5mg by 2.5mg per 3 months. The 5mg is the final target maintained dose. In the treatment, if the relapse occurs, the dose of prednisone returned to the last dosage. For example, if the patient gets a relapse at the dose of 15mg of prednisone, then the dose of prednisone returned to 20mg. The relapse of TAK is defined according to the "2018 Update of the EULAR recommendations for the management of large vessel vasculitis". Relapse includes major relapse or minor relapse. Major relapse: Recurrence of active disease with either of the following: a. Clinical features of ischemia* (including jaw claudication, visual symptoms, the visual loss attributable to TAK, scalp necrosis, stroke, limb claudication). b. Evidence of active aortic inflammation resulting in progressive aortic or large vessel dilatation, stenosis or dissection. Minor relapse Recurrence of active disease, not fulfilling the criteria for the major relapse. 2. ADA: 40mg bim IH. 3. TCZ: 8mg/kg qm ivgtt. 4. Treatment shift: if the TAK patients in ADA group failed to reach clinical remission at the end of 24th week, they would be shifted to TCZ group starting a new round of induction and complete the rest 24-week follow-up; and vice versa; In the follow-up, the disease remission and related markers are monitored.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date December 31, 2023
Est. primary completion date May 1, 2022
Accepts healthy volunteers No
Gender All
Age group 14 Years to 100 Years
Eligibility Inclusion Criteria: 1. age=14 years old; 2. active: Kerr score= 2; 3. severe: 1. Blood pressure > 180/110mmHg; 2. = 3 branches with the stenotic rate > 70% involved; 3. high degree of organ insufficiency: NYHF III~IV; eGFR (MRDR) 15~ 60ml/min; Exclusion Criteria: 1. Severe organ insufficiency; 2. Acute or chronic active infections including tuberculosis, hepatitis virus, etc.; 3. Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease; 4. malignant tumors; 5. history of severe drug allergy; 6. successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Tocilizumab
The tocilizumab group is prescribed with tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint). After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of tocilizumab is maintained for another 24 weeks, otherwise (resistant), patients would be given adalimumab (40mg.bim.IH.) for 24 weeks instead.
Adalimumab
The adalimumab group is prescribed with adalimumab (40mg.bim.IH) for 24 weeks, and the disease activity is monitored in the follow-up (primary endpoint). After 24 weeks of treatment, if the disease is alleviated (remission), then the usage of adalimumab would be maintained for another 24 weeks, otherwise (resistant), patients would be given tocilizumab (8mg/kg.qm.ivgtt.) for 24 weeks instead.

Locations

Country Name City State
China Department of Rheumatology in Zhongshan hospital, Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease remission at 24 weeks. comparison of clinical remission rate between adalimumab and tocilizumab groups at the end of 24th week follow-up; 24 weeks
Secondary Disease remission at 48 weeks. comparison of clinical remission rate between adalimumab and tocilizumab groups at the end of 48th week follow-up; 48 weeks
Secondary Prednisone dose reduction at endpoint comparison of targeted prednisone usage between adalimumab and tocilizumab groups at the end of 24th and 48th week follow-up; 24 weeks and 48 weeks.
Secondary disease relapse in the follow-up comparison of disease relapse between adalimumab and tocilizumab groups; (Relapse is defined as: (1) Major relapse: Major relapse Recurrence of active disease with either of the following: a. Clinical features of ischaemia* (including jaw claudication,visual symptoms, visual loss attributable to TAK, scalp necrosis, stroke, limb claudication). b. Evidence of active aortic inflammation resulting in progressive aortic or large vessel dilatation, stenosis or dissection. (2) Minor relapse: Recurrence of active disease, not fulfilling the criteria for a major relapse.) At the time point of 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 36 weeks, 48 weeks.
Secondary Vascular progression in angiographic examination at 6 months and 12 months. comparison of vascular change with MRA, CTA, or doppler ultrasound angiographic examinations between adalimumab and tocilizumab groups; 24 weeks and 48 weeks.
Secondary Change of the quality of life with questionnaire SF-36 comparison of quality of life between adalimumab and tocilizumab groups with the 36-Item Short Form Health Survey questionnaire (SF-36) (Scores:0~100, lower score means more disability) At the time point of 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 36 weeks, 48 weeks.
Secondary Change of the quality of life with questionnaire MOS-sleep scale comparison of quality of life between adalimumab and tocilizumab groups with the questionnaire of sleep scale from medical outcomes study (MOS-sleep scale) (Scores: 11-65, lower scores indicates more difficulty in sleep) At the time point of 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 36 weeks, 48 weeks.
Secondary Change of the quality of life with the Fatigue severity scale comparison of quality of life between adalimumab and tocilizumab groups with the Fatigue severity scale (Scores: 9-63, higher score means severe fatigue) At the time point of 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks, 36 weeks, 48 weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05243134 - The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Completed NCT02486874 - Clinical Evaluation of PoreSkin Phase 1
Active, not recruiting NCT04592640 - Stem Cells for Uremic Calciphylaxis Patients N/A
Recruiting NCT04599686 - Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer N/A
Recruiting NCT03351842 - Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20% Phase 2
Completed NCT03439930 - The Effect of Balance Training on Neuromuscular Control in Subjects With CAI N/A
Completed NCT02782442 - Cognitive Training Delivered Remotely to Individuals With Psychosis (ROAM) N/A
Not yet recruiting NCT05537155 - Buccal Acupuncture for Delirium Treatment in Older Patients Recovering From Orthopedic Surgery N/A
Recruiting NCT02971982 - PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT02820272 - Water for Reducing Pain in Negative Pressure Wound Therapy Phase 2
Completed NCT00984958 - Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure N/A
Completed NCT00575224 - Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9 Phase 4
Completed NCT00164307 - Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Phase 1/Phase 2
Completed NCT00164528 - Intervening With Children/Adolescents With FAS/ARND Phase 1/Phase 2
Recruiting NCT04603586 - Stereotactic Radiotherapy in Locally Advanced Pancreatic Cancer With Different Biological Effective Doses N/A
Recruiting NCT03375424 - Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany N/A
Not yet recruiting NCT04062370 - Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion Phase 4
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Completed NCT04661228 - Diagnostic Survey of Mental and Substance Use Disorders in HUNT (PsykHUNT)
Recruiting NCT03365141 - Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo N/A